With the cell-engineering technology of choice, MaxCyte is driving a new generation of cell-based therapies, particularly in gene editing and immune-oncology.
We provide our patented, high-performance cell-engineering platform to biopharmaceutical partners engaged in drug discovery and development, biomanufacturing and cell therapy, including gene editing and immuno-oncology. With our robust delivery platform, our team of scientific experts helps our partners unlock the potential of their products and solve development and commercialization challenges.
This platform allows for the engineering of nearly all cell types, including human primary cells, with any molecule, at any scale. It also provides unparalleled consistency and minimal cell disturbance – facilitating rapid, large-scale, clinical- and commercial-grade cell-engineering in a non-viral system and with low-toxicity concerns. Our cell-engineering platform is FDA-cleared, providing our customers and partners with an established regulatory path to commercialize cell-based medicines.
